Document Detail


Resveratrol prevents the development of pathological cardiac hypertrophy and contractile dysfunction in the SHR without lowering blood pressure.
MedLine Citation:
PMID:  19942861     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Cardiac hypertrophy is a compensatory enlargement of the heart in response to stress such as hypertension. It is beneficial in reducing stress placed on the heart. However, when the stress is of a chronic nature, it becomes pathological and leads to cardiac dysfunction and heart failure. Current treatments for hypertension and heart failure have proven beneficial but are not highly specific and associated with side effects. Accordingly, there is an important need for alternative strategies to provide safe and effective treatment.
METHODS: Ten-week-old male spontaneously hypertensive rats (SHRs) and Wistar-Kyoto (WKY) rats were treated with resveratrol (2.5 mg/kg/day) for a period of 10 weeks. Systolic blood pressure, and cardiac structure and function were measured in all groups at different time points of resveratrol treatment. Oxidative stress was also determined in all groups after 10 weeks of resveratrol treatment.
RESULTS: SHRs were characterized with high blood pressure and concentric hypertrophy from 15 weeks of age. Cardiac functional abnormalities were also evident in SHR from 15 weeks onwards. Resveratrol treatment significantly prevented the development of concentric hypertrophy, and systolic and diastolic dysfunction in SHR without lowering blood pressure. Resveratrol also significantly reduced the oxidative stress levels of cardiac tissue in SHR.
CONCLUSIONS: Resveratrol treatment was beneficial in preventing the development of concentric hypertrophy and cardiac dysfunction in SHR. The cardioprotective effect of resveratrol in SHR may be partially mediated by a reduction in oxidative stress. Thus, resveratrol may have potential in preventing cardiac impairment in patients with essential hypertension.
Authors:
Sijo J Thandapilly; Peter Wojciechowski; John Behbahani; Xavier L Louis; Liping Yu; Danijel Juric; Melanie A Kopilas; Hope D Anderson; Thomas Netticadan
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't     Date:  2009-11-26
Journal Detail:
Title:  American journal of hypertension     Volume:  23     ISSN:  1941-7225     ISO Abbreviation:  Am. J. Hypertens.     Publication Date:  2010 Feb 
Date Detail:
Created Date:  2010-01-20     Completed Date:  2010-03-09     Revised Date:  2013-06-03    
Medline Journal Info:
Nlm Unique ID:  8803676     Medline TA:  Am J Hypertens     Country:  United States    
Other Details:
Languages:  eng     Pagination:  192-6     Citation Subset:  IM    
Affiliation:
Heart Failure Research Laboratory, Canadian Centre for Agri-Food Research in Health and Medicine, Department of Physiology, University of Manitoba, Winnipeg, Manitoba, Canada.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Aging / physiology
Animals
Antioxidants / metabolism,  therapeutic use*
Blood Pressure / drug effects*
Cardiomegaly / prevention & control*,  ultrasonography
Echocardiography
Heart Function Tests
Hypertension / complications,  drug therapy,  genetics
Lipid Peroxidation / drug effects
Male
Myocardial Contraction / drug effects*
Oxidative Stress / drug effects
Rats
Rats, Inbred SHR
Rats, Inbred WKY
Stilbenes / therapeutic use*
Grant Support
ID/Acronym/Agency:
//Canadian Institutes of Health Research
Chemical
Reg. No./Substance:
0/Antioxidants; 0/Stilbenes; Q369O8926L/resveratrol
Comments/Corrections
Comment In:
Am J Hypertens. 2010 Feb;23(2):115   [PMID:  20087327 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Assembly of a beta2-adrenergic receptor--GluR1 signalling complex for localized cAMP signalling.
Next Document:  Association of renal artery stenosis with aortic jet velocity in hypertensive patients with aortic v...